Third Rock Ventures
-
Third Rock Ventures Launches Ember Therapeutics with $34M
Private Equity Hub &bull Dec 15, 2011
Boston-based Third Rock Ventures has unveiled a new company, Ember Therapeutics, a product-focused company that's trying to harness breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Third Rock, a venture firm that helps… Full Story »
-
Aileron Expands Roche Deal, Agios Gets $78M, Genzyme MS Drug Advances, & More Boston-Area Life Sciences News
X-Conomy &bull Nov 18, 2011
Cambridge, MA-based Genzyme revealed that its experimental multiple sclerosis treatment, alemtuzumab (Lemtrada), significantly reduced relapses and disability in a Phase 3 trial where it was tested head-to-head against Rebif, a form of interferon sold by EMD Serono and Pfizer. The… Full Story »
-
Boston VC news in brief - Agios raises $78M, Seniorlink raises $5M
Biz Journals &bull Nov 17, 2011
Agios Pharmaceuticals, a biotechnology start up focused on developing new cancer treatments, has raised $78 million in an oversubscribed series C round of funding. The Cambridge company said Flagship Ventures, Third Rock Ventures and ARCH Venture Partners took part in… Full Story »
-
Agios Nabs $78M From Partner Celgene, Existing VCs, and Public Funds
X-Conomy &bull Nov 17, 2011
Cambridge, MA-based Agios said today it has secured $78 million in an oversubscribed Series C financing. Included in this round are Agios's drug-development partner Celgene (NASDAQ: CELG), along with existing investors Arch Venture Partners, Flagship Ventures, and Third Rock Ventures.… Full Story »
-
Agios Pharmaceuticals Seals $78M Series C
Private Equity Hub &bull Nov 17, 2011
Agios Pharmaceuticals , a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated,… Full Story »
-
Agios Secures $78 Million in Oversubscribed Series C Financing
Venture Capital News &bull Nov 17, 2011CAMBRIDGE, Mass., November 17, 2011-- Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that is has secured $78 million in an oversubscribed Series C financing. The proceeds of this financing will be used to advance the companys rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to… Full Story »
-
Allena Pharmaceuticals Launches with $15M
Private Equity Hub &bull Nov 16, 2011
Allena Pharmaceuticals Inc. , a company developing oral protein therapeutics, has raised $15 million in a first round of venture funding. Bessemer Venture Partners , Frazier Healthcare and Third Rock Ventures led the Series A round. The funding will help… Full Story »
-
Allena Pharma Launches With $15M From Third Rock and Other Top-Tier VCs
X-Conomy &bull Nov 16, 2011
Allena Pharmaceuticals, based in Newton, MA, is announcing today that it has started up and raised $15 million in a Series A financing round, led by Third Rock Ventures, Frazier Healthcare, and Bessemer Venture Partners. The new company is pursuing… Full Story »
-
Kleiner Perkins, Google Ventures Join Expanded $33.5M Round for Foundation Medicine
X-Conomy &bull Oct 18, 2011
Foundation Medicine has added a couple more big names to its roster of investors and partners. The Cambridge, MA-based company, seeking to develop personalized cancer diagnostics based on new understanding of genomics, said today it has added Kleiner Perkins Caufield… Full Story »
-
Third Rock Ventures Launches SAGE Therapeutics
Private Equity Hub &bull Oct 18, 2011
Third Rock Ventures has launched SAGE Therapeutics with a $35 million Series A financing. SAGE's efforts focus on advancing a pipeline of new, critically needed treatments for some of the most disabling central nervous system (CNS) disorders such as schizophrenia,… Full Story »
-
TOPICA Pharmaceuticals Closes $27M Series B
Private Equity Hub &bull Oct 18, 2011
Third Rock Ventures , Prospect Venture Partners and Yasuda Enterprise Development Corp. have poured $27 million into privately held biotechnology company TOPICA Pharmaceuticals . The Series B round will be used for continued development of the company's broad-spectrum topical antifungal… Full Story »
-
TOPICA Announces Completion of $27 Million Series B Financing
Yahoo Finance &bull Oct 18, 2011
PALO ALTO, CA-- - TOPICA Pharmaceuticals, Inc. , a privately held biotechnology company, today announced that it has raised $27 million in a Series B financing, led by Third Rock Ventures and existing ... Full Story »
-
Foundation Medicine Closes A Round with $33.5M
Private Equity Hub &bull Oct 18, 2011
Foundation Medicine Inc. , a Cambridge, Mass.-based cancer diagnostics company, has added to its Series A financing, closing the round with $33.5 million. New investors Kleiner Perkins Caufield & Byers and Google Ventures join Third Rock Ventures in the round.… Full Story »
-
Foundation Medicine Closes Expanded Series A Financing Totaling $33.5 Million; Kleiner Perkins Caufield & Byers and Google Ventures Join as Investors
Yahoo Finance &bull Oct 18, 2011
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine care, today announced that the company has closed an expanded Series A financing, bringing the total raised in the round to $33.5 million. In addition to founding investor Third Rock Ventures, this financing includes new investors Kleiner Perkins Caufield & Byers (KPCB) and Google Ventures. In conjunction with the financing, Brook Byers, partner, KPCB, and Krishna Yeshwant, M.D., partner, Google Ventures, will join Foundation Medicine's board of directors. KPCB has a tremendous track record for building valued diagnostic companies, and… Full Story »
-
Third Rock Ventures Launches SAGE Therapeutics to Address CNS Disorders with Critical Unmet Needs
Yahoo Finance &bull Oct 18, 2011
BOSTON--(BUSINESS WIRE)-- Third Rock Ventures, LLC today announced the formation of SAGE Therapeutics. The company was launched with a $35 million Series A financing. SAGE's efforts focus on advancing a broad pipeline of new, critically needed treatments for some of the most disabling central nervous system (CNS) disorders such as schizophrenia, depression, pain and traumatic brain injury (TBI). SAGE Therapeutics is founded on a proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform that will enable the rapid development of a novel class of allosteric receptor modulators. Steven Paul, M.D., the former executive vice president for science and technology and… Full Story »
-
Foundation closes $33.5m tranche from Google, KPCB
AltAssets &bull Oct 18, 2011
Founding investor Third Rock Ventures has led a team of new investors including Kleiner Perkins Caufield & Byers (KPCB) and Google Ventures in a $33.5m Series A financing round for Foundation Medicine, a cancer diagnostics company that aims to bring… Full Story »
-
Eleven Biotherapeutics Dials Up New CEO, Primes Lead Eye Drug for Clinic Next Year
X-Conomy &bull Sep 22, 2011
There's a running joke at Cambridge, MA-based Eleven Biotherapeutics. It shouldn't be a surprise, since the company draws inspiration for its name from the 1984 rock mockumentary "This is Spinal Tap" in which one of the dim-witted members of the proudly band cranks… Full Story »
-
Sabet and Wilson Out at Twitter, Hirshland Out at Polaris, & More VC Comings and Goings
X-Conomy &bull Sep 22, 2011
Bijan Sabet of Spark Capital and Fred Wilson of Union Square Ventures are leaving the board of Twitter at the end of this month. Sabet and Wilson were early investors in the social-media giant, and there has been plenty of… Full Story »
-
Foundation Medicine Grabs $10M
X-Conomy &bull Aug 23, 2011
Foundation Medicine, a Cambridge, MA-based cancer diagnostics startup, has raised $10 million of a targeted $20.5 million round of equity funding, from one investor, and SEC filing reveals. Last year Foundation announced it had raised the first part of a… Full Story »
-
The 5 biggest venture capital deals in Boston, this July
Biz Journals &bull Jul 29, 2011
Zafgen's obesity drug candidate is headed into Phase 2 trials, after the company brought down July's biggest round of venture capital financing for a Massachusetts firm, raising $33 million with Atlas Venture and Third Rock Ventures. Though there were no… Full Story »
